SPY313.48-2.70 -0.85%
DIA257.46-3.26 -1.25%
IXIC10,469.15-23.36 -0.22%

Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $45

Citigroup maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $66 to $45.

Benzinga · -

Citigroup maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $66 to $45.